Braf V600e
The most common cancer-driving mutation in the BRAF gene, targeted by several approved drugs.
If Braf V600e is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Cost-effectiveness analysis of triplet therapy of encorafenib, binimetinib, and cetuximab for treatment of metastatic BRAF V600E-mutated colorectal cancer in China. · Front Pharmacol · 2026-08-10
- A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC. · Pharmacol Res · 2026-08-06
- Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A Case Report From the AGMT mCRC Registry · Clinical Colorectal Cancer · 2026-08-02
- A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3 · Annals of Oncology · 2026-08-02
- CDK9 inhibition sensitizes intrinsically resistant BRAF V600E mutant colorectal cancer to BRAF inhibitors. · Acta Pharm Sin B · 2026-05-18
- Clinical utility and cost-effectiveness of universal tumor screening to identify Lynch syndrome in patients with stage II/III colorectal cancer: a prospective observational study in Japan. · Int J Clin Oncol · 2026-08-04
What the reporting says
It shows up alongside Braf (31), Colorectal Cancer (22).
Two steps out: Chen (through Colorectal Cancer, 22 shared stories on the weaker link); ctDNA (through Colorectal Cancer, 22 shared stories on the weaker link); Egfr (through Colorectal Cancer, 22 shared stories on the weaker link); Immunotherapy (through Colorectal Cancer, 22 shared stories on the weaker link).
Tracked since Apr 2, with coverage on 24 separate days — concentrated in Oncology and Pubmed Targeted.